Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Journal of Commercial Biotechnology

06:08 EDT 1st April 2020 | BioPortfolio

Here are the most relevant search results for "Journal of Commercial Biotechnology" found in our extensive news archives from over 250 global news sources.

More Information about Journal of Commercial Biotechnology on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Journal of Commercial Biotechnology for you to read. Along with our medical data and news we also list Journal of Commercial Biotechnology Clinical Trials, which are updated daily. BioPortfolio also has a large database of Journal of Commercial Biotechnology Companies for you to search.

Showing News Articles 1–25 of 45 from Journal of Commercial Biotechnology

Saturday 29th February 2020

Industry drug development portfolio forecasting: productivity, risk, innovation, sustainability

Multiple factors may affect industry performance, risk, innovation and sustainability in coming years such as long-term economic trends, patents expiration, demographic shifts, and regulatory issues.   Currently available industry-wide prediction frameworks have limited capabilities. They are based on: (1) analysts’ consensus; (2) extrapolation of current trends; (3) financial performance o...

Loss of Control of a Biosimilar Joint Venture and Remeasurement at Fair Value

Samsung BioLogics recognized a big valuation gain when it lost control over a biosimilar joint venture. The investment community expressed concerns about the revaluation gain because the loss of control of the joint venture was attributable to potential voting rights held by the joint venture partner and Samsung BioLogics had incentives to present higher profitability prior to IPO. We suggest the ...

Post Financial Crisis Transaction Trends of U.S. Biotechnology Firms

Transactions announcements can signal the health of an industry. This article examines all biotechnology transaction announcements occurring in the U.S. between 2010 and 2017. A baseline comparison to the pre-financial crisis transaction announcements of 2002 through 2006 is provided. Our study finds a significant rebound in the number of transactions during the time of study and continuing shifts...

Bioenterprise Media Strategy 2020

In 2012 and 2016, the first two strategic science-business media models were published (SBBMM 1.0 and 2.0). Since that time, there have been significant changes both to the media landscape and to the usage and capability of online and social media platforms. This paper seeks to describe the current bioindustry-relevant media landscape, to introduce a new media model, the Strategic Bioenterprise Me...

Using Real Options to Estimate the Pre-commercialisation Value of a Drought Tolerant Wheat Trait

Uncertainty, sunk investment costs and managerial flexibility means standard investment budgeting methods such as net present value are ineffective and undervalue risky investments. Real options attains a more accurate and comprehensive assessment of investments. In this study, we apply a real options analytical framework to investment decisions during the research and development (R&D) proces...

Thursday 21st November 2019

Accessing Continuous Glucose Monitoring (CGM) Sensors in France and the US

Blood sugar monitoring is at the heart of every type one diabetic’s treatment. Because patients need make 500,000 decisions over a lifetime on average, reliability on monitoring devices is vital. Thus, the development of Continuous Glucose Monitoring (CGM) systems came as a revolution, as patients need not prick their fingers anymore and now have access to previously unavailable blood sugar tren...

A state of the art in genetic improvement of Asparagus plants: Patent based perspective.

Asparagus is an important medicinal plant having multiple applications in the various treatment systems. Advances in field of biotechnology has resulted in researchers genetically manipulating medicinal plants to create desired biochemical profile. The present review explores applications of genetic engineering in wild species of Asparagus. The search revealed that most of the patents were targete...

Valuing Carryforwards for the Small Cap Biotechnology Subindustry

Under the 2017 tax law, carryforward rules for net operating losses (NOLs) allow corporations to apply these losses forward for up to twenty years of taxable income. Startup corporations primarily engaged in basic research or that require rapid growth to be sustainable can go a number years with no positive earnings and thus accumulate net operating losses. These losses can be used to reduce tax o...

Patents and Diagnostic Methods in the U.S.: The Subject Matter Eligibility Trap

Diagnostic methods have been gaining medical recognition and social importance as innovations that can be useful to provide individuals with a diagnosis, prognosis or prediction with regard to a condition that they currently have or that they are in risk of developing. Despite the great amount of resources deployed to produce these health technologies and their potential benefits for healthcare sy...

How Should Start-Up Biotechnology Companies Manage Learning and Generate the Necessary Knowledge to Achieve an Alliance-Based Stage of Growth

Ethical drugs can take hundreds of millions of dollars and over 10 years to bring to market. Start-up biotechnology companies are recognized for their unique exploration and then exploitation in the development of future drugs. However, these potential new drugs are highly unpredictable and require a broad scope of inquiry. Significant and complex knowledge along with openness to learning is requi...

USDA Reorganization Should Reduce Biotech Regulation and Feds’ Involvement in the Organic Industry

Recently the USDA proposed measures to “improve efficiencies” and help rural communities in “achieving prosperity.” The measures will not achieve such a goal. If “prosperity” is really USDA’s aim, we offer two suggestions to spur agricultural innovation and free farmers, agricultural scientists and businessmen to prosper. First, the USDA should end the unscientific regulation of mole...

Saturday 7th September 2019

The R&D Marketing Interface in Biopharma and MedTech

This article highlights the importance of building a marketing led cross-functional team that integrates the R&D, and commercialization process in an early stage Biopharma and MedTech company. Marketing should play a prominent role in the cross-functional team at the earliest stages of company formation and product development to identify unmet need, design the development plan, shape the prod...

The Complexity of Pharmaceutical Prices: An Economic Analysis

This article examines the complexity of pharmaceutical pricing. Specifically, list prices are often considerably higher than net prices. PBMs have considerable market power to obtain substantial discounts (rebates) from pharmaceutical companies which encourages higher list prices. In general the generic market work well. At issue is how much of the discounts are passed on to other stakeholders. Hi...

When an FDA Drug Approval Makes Mainstream News: The Announcement of Zulresso, A Media Case Study

Media coverage following U.S. Food and Drug Administration (FDA) drug approvals is generally found in two sectors: bioindustry news and the financial markets. The March 19, 2019 FDA announcement of its approval of the postpartum anti-depression biopharmaceutical Zulresso from Sage Therapeutics also elicited unusually high levels of media response in the mainstream media. This case study (1) detail...

Setting Up and Working with a Board of Directors: A Guide for Startups

Commercializing the idea behind the next big thing is only the first step on a long road to success for a company founder. Facing a myriad of regulatory obstacles, funding challenges, and other seemingly insurmountable roadblocks, every startup needs the support and guidance of an experienced board of directors. A board of directors’ most important function is to provide a continuous give-and-ta...

Building and Managing Great Teams: An Evidence-Based Approach

Efforts to initiate new startups rely heavily on teams and networks. Research demonstrates that 95 percent of the individuals trying to start a business involved others in helping build the new business. This article provides an overview of the team performance literature that can be used when making managerial decisions about building and managing successful entrepreneurial teams. I integrate and...

Leading and Managing Teams in Entrepreneurial Organizations: an Experiential Perspective

This article focuses on summarizing best practices for leading and managing diverse teams in entrepreneurial companies. Our approach is to build on sound academic principles, but we focus on bringing in a strong experiential perspective based on extensive discussions with active venture capital investors in the Silicon Valley/Bay Area innovation ecosystem. A sidebar article summarizes these findin...

“The Good, the Bad, the Ugly”: Leadership Lessons From two Companies – Amgen and Theranos

We review two books that provide perspective on leadership challenges and best practices for building successful companies. Lessons and frameworks are extracted from our reviews of recent books focused on two high-profile life science companies, Amgen and Theranos. Amgen, a pioneer in commercializing biotechnology was very successful, and along with Genentech set the standard for how to build and ...

Strategic Planning for Financing and Growing Biotechnology Companies

There are significant aspirations from both start-ups and existing biotechnology companies, as they endeavor to finance and grow their innovation. Growth demands substantial investments of time, energy and finance. Additionally, they face major risks and uncertainties in the process of growth and new product development in what is a dynamically changing environment. There is no question that the e...

Founding and Funding a Life Sciences Company: An Overview

Founding and funding a company demands that the founding team and their advisors identify and articulate the myriad of challenges and risks that they will face in pursuit of their vision. These factors have implications regarding the technology, market, and team in addition to the regulatory and reimbursement challenges. This article provides the perspective of senior industry investors and legal ...

2018 Mostly a Sideways Market Masking a Lot of Excitement: Innovation and Science Keep the Party Rolling

Building science and technology-based organizations requires a reliable and steady stream of funding across the life cycle of the company. Along with building a good team, building a network of reliable and high value partners is essential. The financial community itself, however goes through periods of “ups and downs” and synchronizing financial strategy with reality can be challenging. There...

Intellectual Property – Solidify Your Competitive Edge

This article notes that startup companies are temporary organizations in search of a repeatable and scalable business model that provides the organization with the ability to scale and grow while minimizing or preferably eliminating competition. This goal is achieved thru use of our Intellectual Property Pyramid TM (IPP) which is an analysis technique that accounts for both the market and the pate...

Intellectual Property for Life Science Entrepreneurs

This article provides an overview of the various forms of intellectual property that are available for life science entrepreneurs. These include patent, trademarks, trade secrets, and copyrights. Intellectual property strategies are suggested including portfolio development. We also cover patent terms, ownership, and exclusivity provisions. Additionally, we consider the synergies between patent st...

IP Fundamentals – What Every CEO Should Know About IP in Biotechnology

This chapter addresses four essential components of Intellectual Property as it relates to patents: (1) patents and the patent process, (2) developing a strategy to maximize patent protection for a product or a process, (3) due diligence, and (4) issues of inventorship and ownership. By way of an overview, there are four basic types of Intellectual Property – Patents, Trademarks, Copyrights and ...

Four Models for Corporate Transformative, Open Innovation

Four models are identified for organizations to pursue simultaneous core growth and transformative innovation leveraging open innovation principles: 1) corporate accelerators —engage with or create autonomous startups; 2) external startup platforms — engage with startups through established third parties, 3) consortia or alliances — leverage resources of peers and emergent players acros...


Quick Search

News Quicklinks